WO2022149568A8 - ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール - Google Patents

ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール Download PDF

Info

Publication number
WO2022149568A8
WO2022149568A8 PCT/JP2022/000040 JP2022000040W WO2022149568A8 WO 2022149568 A8 WO2022149568 A8 WO 2022149568A8 JP 2022000040 W JP2022000040 W JP 2022000040W WO 2022149568 A8 WO2022149568 A8 WO 2022149568A8
Authority
WO
WIPO (PCT)
Prior art keywords
domain
factor
crispr
factors
protein
Prior art date
Application number
PCT/JP2022/000040
Other languages
English (en)
French (fr)
Other versions
WO2022149568A1 (ja
Inventor
達男 伊藤
由梨香 清水
Original Assignee
学校法人 川崎学園
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人 川崎学園 filed Critical 学校法人 川崎学園
Priority to EP22736736.4A priority Critical patent/EP4276182A1/en
Priority to JP2022574050A priority patent/JPWO2022149568A1/ja
Priority to US18/260,452 priority patent/US20240093168A1/en
Priority to CN202280009159.2A priority patent/CN116802287A/zh
Publication of WO2022149568A1 publication Critical patent/WO2022149568A1/ja
Publication of WO2022149568A8 publication Critical patent/WO2022149568A8/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本発明は、へリックス領域を有し、ガイドＲＮＡ及び標的ＲＮＡと複合体を形成でき、かつ、ヌクレアーゼ活性を持たないCRISPR-dCas(dead Cas)タンパク質又はヌクレアーゼ活性を持つCRISPR-Casタンパク質において、前記へリックス領域のＮ末端側を含むＮドメインとＣ末端を含むＣドメイン、刺激に応答して結合可能な第１因子と第２因子を含み、Ｎドメインと第１因子、Ｃドメインと第２因子が各々連結され、第１因子と第２因子はプロテアーゼ認識配列を含むリンカーで結合されるか、或いは、第１因子と第２因子は自己切断ペプチド含むリンカーで結合されるか、或いは、第１因子と第２因子が非共有結合されてなり、（Ｎドメイン）－(第１因子)－(プロテアーゼ認識配列を含むリンカー)－(第２因子)－（Ｃドメイン）、或いは、（Ｎドメイン）－(第１因子)－(自己切断ペプチド含むリンカー)－(第２因子)－（Ｃドメイン）、或いは、（Ｎドメイン）－(第１因子)－(非共有結合)－(第２因子)－（Ｃドメイン）の構造を有するCRISPR-dCas/Casタンパク質誘導体、或いは、（Ｎドメイン）－(第１因子)と(第２因子)－（Ｃドメイン）の２つの部分を有するCRISPR-dCas/Casタンパク質およびタンパク質誘導体セットを提供する。
PCT/JP2022/000040 2021-01-05 2022-01-04 ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール WO2022149568A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP22736736.4A EP4276182A1 (en) 2021-01-05 2022-01-04 Transcriptional product in cells of organism including human, transfected rna, and tool for purifying complex thereof
JP2022574050A JPWO2022149568A1 (ja) 2021-01-05 2022-01-04
US18/260,452 US20240093168A1 (en) 2021-01-05 2022-01-04 Transcriptional product in cells of organism including human, transfected rna, and tool for purifying complex thereof
CN202280009159.2A CN116802287A (zh) 2021-01-05 2022-01-04 包括人类在内的生物体细胞中的转录产物、转染rna及其纯化复合物的工具

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-000378 2021-01-05
JP2021000378 2021-01-05

Publications (2)

Publication Number Publication Date
WO2022149568A1 WO2022149568A1 (ja) 2022-07-14
WO2022149568A8 true WO2022149568A8 (ja) 2022-09-22

Family

ID=82357739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/000040 WO2022149568A1 (ja) 2021-01-05 2022-01-04 ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール

Country Status (6)

Country Link
US (1) US20240093168A1 (ja)
EP (1) EP4276182A1 (ja)
JP (1) JPWO2022149568A1 (ja)
CN (1) CN116802287A (ja)
TW (1) TW202241970A (ja)
WO (1) WO2022149568A1 (ja)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513345A (ja) * 2016-02-10 2019-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 核酸の検知
KR20230156150A (ko) * 2016-06-17 2023-11-13 더 브로드 인스티튜트, 인코퍼레이티드 제vi형 crispr 오솔로그 및 시스템

Also Published As

Publication number Publication date
JPWO2022149568A1 (ja) 2022-07-14
EP4276182A1 (en) 2023-11-15
WO2022149568A1 (ja) 2022-07-14
CN116802287A (zh) 2023-09-22
US20240093168A1 (en) 2024-03-21
TW202241970A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
RU2406729C2 (ru) Новые анти-igf-ir и их применение
Ling et al. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro
IL258029B (en) Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
AU2011262758A8 (en) Anti-tim-3 antibody
ATE330967T1 (de) An her2 bindende peptidverbindungen
JP2020524675A (ja) Ｃｄ３８抗体薬物コンジュゲート
CN114616244A (zh) 特异性结合mage-a的抗原结合蛋白
MY166021A (en) Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
SI2010563T1 (sl) Sintetična MeCP2 sekvenca za proteinsko nadomestno terapijo
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
Eaton et al. Engineering macrophages to control the inflammatory response and angiogenesis
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
EP4292649A3 (en) Fusion protein comprising nerve growth factor and preparation method and use thereof
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
Xu et al. A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing
Murer et al. Targeted delivery of TNF potentiates the antibody-dependent cell-mediated cytotoxicity of an anti-melanoma immunoglobulin
WO2014191391A1 (en) Targeted modulation of macrophages
WO2021074695A8 (en) PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
MX2024002147A (es) Proteina de fusion que contiene anticuerpo anti-tigit y tgf-?r, y composicion farmaceutica y uso de las mismas.
WO2022149568A8 (ja) ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール
WO2021231741A3 (en) Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins
Li et al. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells
Kamimura et al. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22736736

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022574050

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280009159.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022736736

Country of ref document: EP

Effective date: 20230807